Trial Profile
A Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 21 Jul 2023
Price :
$35
*
At a glance
- Drugs Ferumoxytol (Primary) ; Iron sucrose
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Sponsors AMAG Pharmaceuticals
- 18 Jul 2023 Planned primary completion date changed from 31 Mar 2023 to 31 Aug 2023.
- 07 Jun 2022 Planned End Date changed from 31 Jan 2022 to 31 Aug 2023.
- 07 Jun 2022 Planned primary completion date changed from 31 Aug 2021 to 31 Mar 2023.